Sai Life Sciences Limited , a leading Contract Research, Development and Manufacturing Services (CRDMO) provider, has announced its financial results for the second quarter, showcasing a remarkable improvement in both revenue and profitability.

Strong Financial Performance

The company reported a consolidated net profit of 838.44 million rupees for Q2, representing a significant increase from 415.10 million rupees in the same quarter last year. This translates to a year-on-year growth of approximately 102%, effectively doubling the company's bottom line.

Revenue from operations also saw substantial growth, rising to 5,374.70 million rupees compared to 3,955.62 million rupees in the corresponding quarter of the previous year, marking an increase of about 35.9%.

Key Financial Metrics

Here's a breakdown of the key financial metrics for Q2:

Operational Highlights

The company's strong performance can be attributed to its focus on providing high-quality CRDMO services. The significant increase in revenue suggests growing demand for Sai Life Sciences' offerings in the pharmaceutical and biotechnology sectors.

Looking Ahead

As Sai Life Sciences continues to demonstrate strong financial performance, investors and industry observers may be watching closely to see if this growth trajectory can be maintained in the coming quarters. The company's ability to capitalize on opportunities in the evolving pharmaceutical research and manufacturing landscape will be crucial for its future success.

Sai Life Sciences' impressive Q2 results underscore its growing prominence in the CRDMO sector and may position the company favorably for future growth and expansion opportunities.

Sai Life Sciences , a prominent player in the pharmaceutical industry, has announced the allotment of 8,89,133 fully paid-up equity shares under its employee stock option plans. This move, approved by the company's Board of Directors through a circular resolution dated December 19, 2025, aims to attract, retain, and reward employees.

Details of the Latest Allotment

The recent allotment includes shares issued under two distinct employee stock option plans with significantly higher numbers than previous allotments:

Updated Share Capital Structure

Following this substantial allotment, Sai Life Sciences' total issued share capital has increased significantly to 21,12,31,216 shares. The newly allotted shares have been issued in dematerialized form with the ISIN number INE570L01029, with distinctive numbers ranging from 210342084 to 211231216.

Premium and Pricing Details

The company has structured the allotment with specific premium components:

Employee Stock Option Plans Framework

The company's employee stock option plans, ESOP 2008 and MESOP 2018, are designed with a maximum vesting period of 5 years. These plans offer flexibility with multiple vesting options, allowing employees to exercise their options as long as they remain in the company's service. The pricing formula is determined by the Nomination and Remuneration Committee in conformity with applicable accounting standards and SEBI regulations.

Regulatory Compliance and Documentation

Sai Life Sciences has ensured comprehensive compliance with regulatory requirements, filing necessary documents with both BSE Limited and National Stock Exchange of India Limited. The company has adhered to the Securities and Exchange Board of India (SEBI) regulations, including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

This substantial allotment of shares under the employee stock option plans demonstrates Sai Life Sciences' continued commitment to aligning employee interests with the company's long-term growth objectives and talent retention strategy.